Dr Reddy's Laboratories Ltd
F:RDDA
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
1.1T INR |
Loading...
|
|
| ZA |
A
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
48.4B ZAR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
960.1B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
235.6B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
158B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Dr Reddy's Laboratories Ltd
Glance View
In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Dr Reddy's Laboratories Ltd is 65.8%, which is below its 3-year median of 68.9%.
Over the last 3 years, Dr Reddy's Laboratories Ltd’s Gross Margin has decreased from 67.9% to 65.8%. During this period, it reached a low of 65.8% on Jan 1, 2026 and a high of 70.8% on Jun 30, 2024.